Biggest dog drugs in the history of pharmaceuticals

ONZETRA or Nonzetra as one of my paid speakers called it

 

ya, Onzetra is a bust, even if a patient gets a new script none of the patients want to refill it

 

Do you know how stupid our senior leaders are? They set the 2018 sales forecast at $200m. Are we even going to reach $10m this year?

 

It has to be high to justify the deal. No worries as all our "leaders" are trying to leverage their migraine expertise to get on with Amgen or Lilly. Hopefully those companies aren't that stupid.

 

Leaders?! That's hilarious. We have an ED in Med Aff that wouldn't survive a week as an MSL and our commercial leadership are a bunch of castoffs from other places.

 

But at least our leadership has experience with Latisse eye lash growth,
should be very helpful in our tough neurology market.